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The aim of this study is to elucidate the effects of different dosages of octreotide on portal pressure in 
cirrhotic patients and to investigate the mechanism of activated human hepatic stellate cells (HSCs) on 
octreotide. Thirty-one (31) hepatitis B-related cirrhotic patients were randomly assigned to receive 
treatment with a 50 (group A, n = 12) or a 25 µg/h infusion of octreotide for 72 h (group B, n = 14); the 
control group C (n = 5) received conventional treatment. Dynamic portal pressure was directly measured 
via a portal vein catheter. To study the cellular mechanism of octreotide, the expression of SSTRs 1-5 in 
LX-2, an HSC line, was examined by immunostaining and RT-PCR. Intracellular Ca2+ in LX2 was 
measured by laser scanning confocal microscopy (LSCM). The protein and mRNA levels in all five 
subtypes of SSTRs were positively expressed in LX-2. Octreotide led to an immediate two-fold drop in 
intracellular Ca2+ (P < 0.01). Portal pressure, in both groups A and B, decreased significantly (mean, - 
20.6%) after octreotide infusion. Octreotide decreased portal pressure in cirrhotic patients by inhibiting 
HSC contractility by decreasing intracellular Ca2+ concentration via stimulation of all SSTRs on HSCs.  
 





Chronic liver diseases, especially liver cirrhosis, are often 
complicated with portal hypertension, which is 
characterized by increased intrahepatic vascular 
resistance and hyperdynamic states (Blei, 2007; Sanyal 
et al., 2008). Complications associated with portal 
hypertension occurs when  the  portal  pressure  exceeds 
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12 mmHg (Sharara and Rockey, 2001). The most 
frequent and severe complication of portal hypertension, 
gastro-esophageal varices bleeding (EVB), has a high 
mortality rate in patients with cirrhosis (Dragoteanu et al., 
2008; Garcia-Tsao, 2003). Over the last 20 years, marked 
progress in the understanding of the pathophysiology of 
portal hypertension has opened doors to pharmacologic 
treatments. It is assumed that sustained reduction in 
portal pressure by long-term drug administration may 
prevent and treat the complications of portal hypertension 
(Garcia-Tsao et al., 2008; Minor and Grace, 2006). 
Therefore, a major focus of management of patients with 
portal hypertension is to reduce functional portal venous 
flow and portal pressure.  
The growth hormone release inhibitors, native somato-
statin (SST) and its octapeptide analog “octreotide”. They 
are important in the treatment of liver cirrhosis portal 
hypertension complicated by acute EVB, although the 
mechanism of action has not been completely  elucidated 








(n = 12) 
Group B 
(n = 14) 
Group C 
(n = 5) 
Age 47.8 ± 4.2 48.9 ± 5.2 48.2 ± 2.5 
Gender (M/F) 9/3 9/5 4/1 
Child A 7 9 4 
Child B 5 5 1 
Ascites (yes) 0 0 0 
Encepahalopathy (yes) 0 0 0 
EVB history (yes/no) 11/1 14/1 5/0 
 




(Gonzalez et al., 2006; Triantos and Burroughs, 2007). A 
recent study showed that hepatic stellate cells (HSCs), 
the perisinusoidal pericytes, may play an important role in 
the regulation of intrahepatic resistance and micro-
hemodynamics because of their smooth muscular 
characteristics, namely contractility (Reynaert et al., 
2004; Song et al., 2004; Xu et al., 2005). HSC contrac-
tility is regulated by intracellular Ca2+ and certain vaso-
active factors (Ding et al., 2004; Reynaert et al., 2002). 
Although the precise contractile and regulatory mecha-
nisms of HSCs are not as well studied as smooth muscle 
cells, many studies have described intracellular Ca2+ 
signaling pathways and proteins involved in HSC 
contraction (Ding et al., 2004; Reynaert et al., 2002; 
Reynaert et al., 2001; Xu et al., 2005). Therefore, HSC-
targeted therapy may play an important role in reducing 
portal venous pressure and improving a hyperdynamic 
circulatory state.  
SST and its analogues are now the preferred medi-
cation in the treatment of liver cirrhosis portal hyperten-
sion complicated by EVB, while octreotide is used more 
widely in clinical practice (Sharara and Rockey, 2001). 
The mechanism of SST and octreotide in reducing portal 
pressure is still under debate. Song et al. (2004) showed 
that there is strong mRNA expression of SSTR subtypes-
SSTR2, STR3 and SSTR5, but not SSTR1 and SSTR4 in 
rat HSCs. It is thought that octreotide may affect HSCs 
via SSTR and thereby exert its biological activity. 
However, other authors have reported strong staining of 
SSTR1, SSTR2 and SSTR3 in activated rat HSCs, but 
not in normal liver. SST causes significant partial inhi-
bition of ET-1-induced contraction of HSC, mainly via 
stimulation of SSTR1 (Reynaert et al., 2001). The 
purpose of this study was to determine the patterns of 
expression of five SSTR subtypes in human activated 
HSCs, while also studying the effects of octreotide on 
intracellular Ca2+ in the regulation of HSC contractility. 
The effects of two dosages of octreotide on portal 
pressure in cirrhotic patients with portal hypertension 
were determined. This study may provide important 
guidance for the rational clinical use of octreotide and 








Thirty-one (31) hepatitis B-related cirrhotic patients with portal 
hypertension were enrolled in a randomized, open study. Twenty-
two (22) male and 9 female patients participated with a mean age of 
48.6 years. A diagnostic work-up was performed that included a 
physical examination, laboratory tests and B-ultrasonography or 
computerized tomography (CT) scan, according to the criteria 
suggested by the Chinese Medical Association for Liver Diseases in 
2000. A gastrointestinal endoscopic examination demonstrated that 
the number of patients with severe and moderate esopha-
geal/gastric varices were 29 and 2, respectively. Of these patients, 
29 patients had undergone surgery because of portal hypertension 
with a history of variceal bleeding. The other patients had voluntarily 
undergone surgery because of severe esophageal varices with 
hypersplenia. The number of patients with Child-Pugh grade A and 
B cirrhosis were 20 and 11, respectively.  
In addition to the splenectomy, paraesophagogastric devascular-
isations were routinely performed, which, in brief, entails making an 
oblique incision under the left costal border. During the surgery, the 
extremity of a single lumen venous catheter (7F SPECATH, Beijing, 
China) was inserted into 5 cm of the main stem of the portal vein 
through the right gastro-omental vein and the proximity was fixed on 
the right abdominal wall. The purpose of the portal vein catheter 
was to prevent portal vein thrombosis after splenectomy and devas-
culation and to monitor the portal pressure (Lin et al., 2007). The 
catheter was irrigated with heparinized saline (heparin, 25 unit/ml), 
connected to a three-way tube and the heparin cap was prepared.  
The patients were randomly divided into three groups using the 
lot-drawing method after 24 h of surgery. In group A, the patients (n 
= 12) received a bolus of octreotide (100 µg) followed by a 
continuous infusion of 50 µg/h and conventional treatment for 3 
days. Patients in group B (n = 14) received a bolus of octreotide 
(100 µg) followed by a continuous infusion of 25 µg/h and 
conventional treatment for 3 days. Patients in group C (n = 5) 
received conventional treatment, which was regarded as placebo 
control. The baseline characteristics of the study subjects, including 
mean age, gender and Child-Pugh grades and conventional 
treatment in groups A, B and C were comparable as shown in Table 
1. The study was explained to the patients and/or their relatives and 
consent was obtained from all patients. The study protocol was 
approved by the Ethical Committee of Beijing You’an Hospital of 
Capital Medical University.  




Table 2. Primer sequences for amplification of SSTR subtypes 1-5 and reference gene GAPDH.  
 
Receptor Upstream Downstream 
Amplified 
fragment (bp) 
SSTR1 5'-AGCCGGTTGACTATTACGCC-3' 5'-GCTCTCACTTCTACCATTGTC-3' 334 
SSTR2 5'-GGTGAAGTCCTCTGGAATCC-3' 5'-CCATTGCCAGTAGACAGAGC-3' 461 
SSTR3 5'-TCATCTGCCTCTGCTACCTG-3' 5'-GAGCCCAAAGAAGGCAGGCT-3' 221 
SSTR4 5'-CGGCAGTCTTCGTGGTCTAC-3' 5'-GCATCAAGGCTGGTCACGAC-3' 247 
SSTR5 5'-AACACGCTGGTCATCTACGTGGT-3' 5'-AGACACTGGTGAACTGGTTGAC-3' 211 




Dynamic measurement of portal pressure 
 
The catheter was irrigated with heparinized saline (heparin, 25 
unit/ml) and the three-way tube and heparin cap were connected. 
The pre-devascularization portal venous pressure was measured 
and the zero point was defined using the mid-axillary line level. The 
proximity of the single lumen venous catheter was connected to the 
monitor (Hp M3) through a pressure transducer. After 24 h when the 
patient’s vital signs were stabilized, the portal venous pressures 
were measured before drug administration (regarded as baseline), 
5 min, 15 min, 60 min, 2 h, 24 h, 48 h and 72 h after drug 
administration and 15 min, 30 min, 60 min, 24 h and 48 h after drug 
withdrawal. The change in portal pressure was calculated as: portal 
pressure (%) = (baseline-portal pressure)/ baseline × 100. The 
catheter was safely removed after the investigation at 7 days. No 
complications related to insertion of the catheter were observed. All 
patients recovered from their surgery. 
 
 
Human HSC culture 
 
The activated human HSC cell line, LX-2, which was established 
from healthy HSCs transfected with SV40 and selectively cultured 
with medium containing a low concentration of fetal bovine serum 
(FBS), was donated by Professor JD Jia (Liver disease center, 
Beijing Friendship Hospital). The phenotype was shown to be 
activated HSCs (Sanyal et al., 2008). Frozen cells were thawed at 
37°C, cultured with Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco BRC, Grand Island, NY ,USA) containing 10% FBS and 
prepared as a HSC single cell suspensions of 8 × 104 cells. LX-2 
was plated on 20 × 20 mm glass coverslips in 35-mm culture dishes 
at a density of 8 × 104 cells/ml and routinely incubated in 2 ml 
DMEM media, supplemented with penicillin, streptomycin and 10% 
FBS for 24 h in a 95% O2/5% CO2 mixture at 37°C. Each 
experiment was repeated 3 times. 
 
 
Measurement of intracellular Ca2+ 
 
Cultured LX-2 cells were observed using a TE300-F70 inverted 
microscope (NIKON, Tokyo, Japan). After the cells were completely 
adherent, the medium was switched to 2 ml of serum-free DMEM 
media. Intracellular Ca2+, loaded by a dosage of 5 µl Flu-3/AM (1:50 
dilution; Biotium, Hayward, CA, USA) for 30 min under 95% air and 
5% carbon dioxide at 37°C, was measured by MRC-1024 type laser 
scanning confocal microscopy (LSCM; Bio-Rad, HERCULES,CA 
,USA) at a 488 nm excitation wavelength and 526 nm emission 
wavelength. Dynamic fluorescence scans of Flu-3 labeled 10 cells 
were randomly selected for detection of intracellular fluorescence 
intensity (FI) using LSCM at a different treatment stage. The 
concentration of intracellular Ca2+ was represented using FI. The 
dynamic changes in intracellular Ca2+ stimulated by octreotide (final 
concentration, 5 µg/ml), endothelin-1 (ET-1, 2 µg/ml) and KCl (2 
mmol/ml) were recorded by LSCM. The effects of octreotide on 





After 24 h of culture of LX-2, the coverslips were washed with PBS 
3 times, fixed in 4% paraformaldehyde for 1 h and then incubated in 
3% H2O2-deionized water at room temperature for 10 min to block 
endogenous peroxidase. A 1:200 ratio of rabbit polyclonal 
antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) 
to mouse antigens (SSTR2/SSTR5) was incubated with the cells at 
37°C for 2 h. After that, cells were incubated with goat anti-rabbit 
IgG antibody-HRP polymer (Beijing Zhongshan Golden Bridge 
Biotechnology Co., Ltd., Beijing, China) at 37°C for 30 min and then 
treated with AEC developing solution. After approximately 7 min, 
when the coloration was good, coverslips were mounted with 
gelatin. Expression of SSTR2 and SSTR5 was examined by a 
cytology specialist. The expression of SSTR1, 3 and 4 of HSCs was 
not carried out because commercial antibodies to mouse antigens 
for SSTR1/SSTR3/SSTR4 are not available. Therefore, we 
designed the following detection methods in order to observe the 





After 24 h of culture of LX-2, total RNA was extracted with Trizol 
reagent (Invitrogen, Carlsbad, CA ,USA) and reverse transcribed to 
cDNA using the Reverse Transcription System (Applied 
Biosystems, Framingham, MA , USA) according to the 
manufacturer’s instructions. SSTR 1-5 primers were designed as 
shown in Table 2, confirmed for accuracy in GenBank and 
mismatched 10 - 11 basic group TC at the downstream primer of 
SSTR4 was changed to CT. In parallel, glyceraldehyde phosphate 
dehydrogenase (GAPDH) was used as an internal negative control 
and its primers were designed as shown in Table 2. 
Diethylpyrocarbonate (DEPC) water used in our laboratory was 
used as negative control. RT-PCR was performed as recommended 
by the manufacturer (Invitrogen). In brief, RT-PCR was carried out 
in a total volume of 25 µl reactions consisting of ddH2O (13.9 µl), 
10× buffer (2.5 µl), 25 mmol/l MgCl2 (25 mM; 1.5 µl), 10 mM dNTP 
(1 µl) and Taq polymerase (0.1 µl; Promega, Madison, WI, USA), 10 
µM upstream and downstream primers (2 µl each), cDNA template 
(2 µl) and 2 µl of parogen. RT-PCR amplification was conventionally 
carried out. 10 µl of PCR reaction was conventional in 20 mg/g 
agarose gel with 100-bp DNA markers. Densitometric analysis of 
PCR products was performed by computer software (Quantity One, 





Statistical  analysis  was  performed  using  the  Student’s   t-test  as 






Figure 1. The immunocytochemical staining showed that SSTR2 (A), SSTR5 (B), labeled with reddish brown 






Figure 2. The results of RT-PCR showed that the mRNA of SSTR subtypes (SSTR1, 2, 3, 4 and 5) in LX-2 cells in A-D. Figure 2A 
shows expression of SSTR1(1) and negative control (2); Figure 2B shows expression of SSTR2(1), SSTR4(3) and negative control 
(2); Figure 2C shows expression of SSTR3(1) and negative control (2); while Figure 2D shows expression of SSTR5(1) and 




given in the Statistical Package for Social Sciences (SPSS11.5). FI 
represented intracellular Ca2+ concentration. Quantitative data were 
expressed as the mean ± SD and analyzed with a paired t-tests and 
Wilcoxon tests, while the chi-squared test was used for semi-






Expression of SSTR 1-5 subtypes in LX-2 
 
Immunocytochemical staining showed that LX-2 cells 
were positive for SSTR2 and SSTR5, which were mainly 
localized on the cell membrane and in the cytoplasm 
(Figure 1). RT-PCR detected mRNA expression of SSTRs 
1-5 in LX-2 cells (Figure 2). Results of gel electrophoresis 
were analyzed and semi-quantified with software Quantity 
 One and the relative levels of expression of SSTR 
subtypes 1 - 5 were found to be SSTR 1, 4 > SSTR 2, 5 > 
SSTR 3 (P < 0.05).  
Effect of octreotide on intracellular Ca2+  
 
Octreotide lowered the intracellular Ca2+ and ET-1 
significantly increased intracellular Ca2+ concentration in 
LX-2 cells (Table 3). KCl, an L-type voltage-dependent 
calcium channel agonist, also increased the intracellular 
Ca2+ concentration in LX-2 cells. Moreover, we also 
showed that octreotide did not inhibit the up-regulation of 
intracellular Ca2+ concentration stimulated by KCl or ET-1.  
 
 
Effect of octreotide on portal pressure in cirrhotic 
patients 
 
Following splenectomy with paraesophagogastric devas-
cularization, the portal venous pressure decreased by an 
average of 15.4%. Portal venous pressure significantly 
decreased after 5 min in both groups A and B and 
octreotide achieved a maximum effect after 24 h, with an 
average decrease in portal venous pressure of 20.6% 





Table 3. The results of intracellular Ca2+ in LX2 cell line 
stimulated by octreotide or ET-1. 
 
FI Octreotide treatment (n = 10) 
ET-1 treatment 
(n = 10) 
Before 8.62 ± 1.32 8.62 ± 1.32 
After 4.31 ± 1.35* 17.6 ± 2.31** 
 
Results are given using mean ± SD; compared with before * P < 




of octreotide, the portal venous pressure decreased by 
23.1% on average in the 48 h following drug withdrawal. 
However, patients in the 25 µg/h octreotide infusion group 
had a tendency for increased portal venous pressure 2 h 
following drug withdrawal and the portal venous pressure 
decreased by 11.6% on average. The portal pressure 
was not significantly changed after surgery in group C 
and the average portal pressure in group C was higher 
compared to either group A or B (P < 0.05). The degree of 
change in the portal venous pressure and the percent of 
portal venous pressure at 24 and 48 h were significantly 
different between groups A and B (P < 0.05). The heart 
rate and mean arterial blood pressure before and after 
octreotide infusion showed no significant differences 





SST and its analogues, particularly the synthetic 
analogue, octreotide, are widely used as first-line 
treatment for liver cirrhosis portal hypertension compli-
cated by variceal bleeding (Masyuk et al., 2007). This 
study demonstrated that a bolus of octreotide (100 µg) 
followed by a continuous infusion of octreotide (25 or 50 
µg/h) can significantly reduce the portal venous pressure 
in these patients. The maximum effect of octreotide was 
observed after 24 h. However, the portal venous pressure 
of patients receiving a 50 µg/h infusion remained at a low 
level 48 h after drug withdrawal, while portal venous 
pressure in the patients who received a 25 µg/h infusion 
increased 2 h after drug withdrawal. This may be the 
pharmacologic basis of the lower re-bleeding rates in 
patients receiving 50 µg/h of octreotide after drug 
withdrawal (Association 2005). Nevertheless, the mecha-
nism of SST/octreotide in reducing portal venous pre-
ssure is not clear (Minor and Grace, 2006; Yang et al., 
2005). Initial studies suggest that the inhibitory effect of 
SST/octreotide on the release of glucagon is the principal 
mechanism by which SST reduces portal venous 
pressure (Yang et al., 2005). Another study indicated that 
a bolus injection of SST caused a maximal decrease in 
variceal and portal pressure within 0.5 - 2 min. Indeed, it 
takes 10 min for maximal inhibition of glucagon secretion 
and the half-life of glucagon is 25 min in the cirrhotic 
model  (Song  et  al.,  2004).   Some   investigators   have  




suggested that octreotide reduces portal venous pressure 
by selectively contracting the superior mesenteric artery 
and causing a reduction of blood flow in the liver (Sharara 
and Rockey 2001). In our previous study, we demon-
strated that octreotide had no direct effect on the 
contraction of vascular smooth muscles (Ding et al., 
2004). 
Intrahepatic vascular resistance can be reduced by 20 - 
30% with drugs (Gonzalez et al., 2006; Sanyal et al., 
2008; Triantos and Burroughs, 2007). Drug acting sites 
must be targeted to factors that reversibly increase 
intrahepatic vascular pressure and/or portal venous blood 
flow. HSCs are located in the perisinusoidal space of 
disse close to sinusoidal endothelia and spread many 
long synapses surrounding the hepatic sinusoids, which 
are in contact with numerous hepatic cells, adjacent 
HSCs, nerve terminals and extend among the hepatic 
cells to adjacent hepatic sinusoids (Sharara and Rockey, 
2001). Activated HSCs have characteristics that are 
similar to smooth muscle cells and the contraction and 
relaxation of HSCs are important regulatory factors of 
intrahepatic resistance and sinusoidal blood flow (Ding et 
al., 2004; Reynaert et al., 2002; Sharara and Rockey, 
2001). Therefore, it is possible that SSTs reduce portal 
venous pressure partly through their action on HSCs.  
Another study indicated that the intracellular Ca2+- 
mediated signal system plays an important role in 
regulating contraction and relaxation of vascular smooth 
muscle cells, while the Rho system of low-molecular-
weight GTPase plays an important role in regulating the 
functions of non-smooth muscle cells (Ding et al., 2004). 
Recent studies have demonstrated that the intracellular 
Ca2+-mediated signal system also plays an important role 
in regulating HSC contraction and relaxation (Ding et al., 
2004; Reynaert et al., 2002). We reported that octreotide 
could significantly and immediately down-regulate Ca2+ 
concentration in HSCs-T6 cells, a cell line established 
from SD rat HSCs transfected with SV40 (Ding et al., 
2004). In the current study, we found that, while 
octreotide could significantly and immediately down-regu-
late the Ca2+ concentration in LX-2 cells, it did not inhibit 
an increase in Ca2+ concentration in HSCs caused by 
KCL-stimulated L-type voltage-operated calcium 
channels (L-VOCC) opening. Nor could it inhibit an 
increase in Ca2+ concentration in HSCs caused by ET-1 
stimulation. We speculate that octreotide down-regulates 
Ca2+ concentration in HSCs, which inhibits HSC 
contraction, thereby reducing intrahepatic resistance and 
portal venous pressure.  
The mechanism of octreotide action may lay in the 
binding of SSTRs on HSCs. SSTR subtypes 1-5 have 
been cloned successfully from human, rat, mice, cow and 
pig and induce many biological effects (Masyuk et 
al.,2007; Reynaert et al., 2004; Reynaert et al., 2001; 
Song et al., 2004). Studies of HSCs expressing an SSTR, 
especially in human HSCs, are rare (Xu et al. 2005). 
Reynaert et al. (Reynaert et al. 2001)  demonstrated  that 




SSTRs 1, 2 and 3 are expressed at the protein and 
mRNA levels in cultured activated rat HSCs, but not in 
normal rat liver. More recently, Reynaert et al. (2001) also 
demonstrated that in normal human liver, both 
hepatocytes and HSC are negative for SSTRs 1-5. 
However, cirrhotic liver and hepatocellular carcinoma as 
well as cultured HSCs, expressed all five SSTRs 
(Reynaert et al., 2004). In the current study, we 
demonstrated that the LX-2 HSC cell line can express all 
five SSTRs at the protein and mRNA levels, providing 
evidence for the possibility that HSCs may be a target 
site of SST in reducing portal venous pressure.  
A pharmacologic study demonstrated that natural SST 
has a high affinity for all SSTRs, while long-acting 
analogues such as octreotide, only have a high affinity for 
SSTR2 and SSTR5, a medium affinity for SSTR3 and 
almost no affinity for SSTR1 and SSTR4 (Song et al., 
2004; Yang et al., 2005). Other studies have indicated 
that natural SST is more effective than octreotide at 
reducing hepatic sinusoidal pressure and this effect might 
be due to an NO-independent mechanism (Gonzalez et 
al., 2006; Yang et al., 2005). In this study, we also 
indirectly demonstrated that HSCs play an important role 
in decreasing portal pressure from the SSTR1-5 aspect, 
suggesting that SST may have better effects in reducing 
hepatic sinusoidal pressure than octreotide. Therefore, 
we considered the possibility that octreotide down-
regulates Ca2+ concentration in HSCs, thereby inhibiting 
the contraction of HSCs, leading to reduced intrahepatic 
resistance and portal venous pressure. The mechanism 
may be one of octreotide combining with specific SSTRs 
on HSCs. These results provide evidence for the 
possibility that HSCs may be the targeted site of action of 
SST and its analogues in reducing portal venous pre-
ssure. Clinical research evaluating SST or octreotide for 
the treatment of portal hypertension should take these 
findings into account. This project may provide important 
guidance for the rational clinical use of octreotide and 






These results provide evidence for the possibility that 
HSCs may be the targeted site of action of SST and its 
analogues in reducing portal venous pressure. Clinical 
research evaluating SST or octreotide for the treatment of 
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